Federal health officials have indicated that BPC-157 and roughly 13 other peptides previously restricted by the FDA could be moved back to legally compoundable status, pending an official regulatory update.
In 2023, the FDA placed BPC-157 on its Category 2 restricted substances list, effectively barring licensed compounding pharmacies from preparing the peptide for patients. The designation was based on insufficient human clinical data despite a large body of animal research showing benefits for gastrointestinal healing, tendon repair, and neuroprotection. The move created significant disruption for both practitioners and patients who had been using compounded BPC-157 under physician supervision.
In early 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 peptides on the FDA Category 2 list are expected to be reclassified to Category 1, restoring compounding access with a prescription. BPC-157 is among the peptides named in that expected reclassification. The announcement stopped short of confirming a timeline or final rule, but it has renewed interest among clinicians and researchers.
The scientific case for BPC-157 remains built primarily on preclinical data. Over 100 rodent studies have examined its effects, and a 2025 systematic review published in PMC evaluated its emerging use in orthopaedic sports medicine, finding encouraging but preliminary evidence. Only a handful of small human pilot studies exist, and formal Phase 2 or Phase 3 trials have not yet been completed. Advocates argue that the peptides safety profile warrants expedited human investigation, while regulators maintain that controlled trials are necessary before broad clinical adoption.
Source: STAT News
Share this article
The Peptide Wizard
High-quality research peptides for lab use. Third-party tested with certificate of analysis available on every product.
Visit The Peptide WizardSponsored content. ThePBrief receives compensation. For research purposes only.